Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.

Serum levels were determined in 434 patients with benign and malignant gastrointestinal diseases and compared with the serum concentrations of carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP). The highest proportion of elevated CA-50 levels (greater than 17 U ml-1) was found in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuusela, P., Haglund, C., Roberts, P. J., Jalanko, H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1987
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002047/
https://www.ncbi.nlm.nih.gov/pubmed/2441731
_version_ 1782135690668015616
author Kuusela, P.
Haglund, C.
Roberts, P. J.
Jalanko, H.
author_facet Kuusela, P.
Haglund, C.
Roberts, P. J.
Jalanko, H.
author_sort Kuusela, P.
collection PubMed
description Serum levels were determined in 434 patients with benign and malignant gastrointestinal diseases and compared with the serum concentrations of carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP). The highest proportion of elevated CA-50 levels (greater than 17 U ml-1) was found in patients with pancreatic cancer (73%). High levels were mainly associated with advanced cancer, but also half of the patients with a resectable pancreatic tumour had an increased CA-50 concentration. The CA-50 level was elevated in 37-58% of patients with colorectal, gastric, hepatocellular and biliary tract cancers. In all gastrointestinal cancers, CA-50 gave additional information compared with CEA and AFP, except in hepatocellular carcinoma where AFP was the best marker.
format Text
id pubmed-2002047
institution National Center for Biotechnology Information
language English
publishDate 1987
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20020472009-09-10 Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases. Kuusela, P. Haglund, C. Roberts, P. J. Jalanko, H. Br J Cancer Research Article Serum levels were determined in 434 patients with benign and malignant gastrointestinal diseases and compared with the serum concentrations of carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP). The highest proportion of elevated CA-50 levels (greater than 17 U ml-1) was found in patients with pancreatic cancer (73%). High levels were mainly associated with advanced cancer, but also half of the patients with a resectable pancreatic tumour had an increased CA-50 concentration. The CA-50 level was elevated in 37-58% of patients with colorectal, gastric, hepatocellular and biliary tract cancers. In all gastrointestinal cancers, CA-50 gave additional information compared with CEA and AFP, except in hepatocellular carcinoma where AFP was the best marker. Nature Publishing Group 1987-06 /pmc/articles/PMC2002047/ /pubmed/2441731 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Kuusela, P.
Haglund, C.
Roberts, P. J.
Jalanko, H.
Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
title Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
title_full Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
title_fullStr Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
title_full_unstemmed Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
title_short Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
title_sort comparison of ca-50, a new tumour marker, with carcinoembryonic antigen (cea) and alpha-fetoprotein (afp) in patients with gastrointestinal diseases.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002047/
https://www.ncbi.nlm.nih.gov/pubmed/2441731
work_keys_str_mv AT kuuselap comparisonofca50anewtumourmarkerwithcarcinoembryonicantigenceaandalphafetoproteinafpinpatientswithgastrointestinaldiseases
AT haglundc comparisonofca50anewtumourmarkerwithcarcinoembryonicantigenceaandalphafetoproteinafpinpatientswithgastrointestinaldiseases
AT robertspj comparisonofca50anewtumourmarkerwithcarcinoembryonicantigenceaandalphafetoproteinafpinpatientswithgastrointestinaldiseases
AT jalankoh comparisonofca50anewtumourmarkerwithcarcinoembryonicantigenceaandalphafetoproteinafpinpatientswithgastrointestinaldiseases

Ejemplares similares